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artial Mechanical
ardiac Support
art of the Solution
r Part of the Problem?*
atrick M. McCarthy, MD
hicago, Illinois
ntuitively it makes sense that providing a significant por-
ion of the cardiac output while unloading the ventricle will
mprove the patient’s hemodynamic status, clinical condi-
ion, and quality of life. This is particularly true for patients
ith milder forms of heart failure. But for those with truly
dvanced end-stage disease and cardiogenic shock, total
ardiac support is typically required. The pragmatic issue is:
ow does one provide partial cardiac support that is effec-
ive, safe, and ideally performed with a minimally invasive
rocedure?
See page 79
In this issue of the Journal, Meyns et al. (1) report on the
ong-term partial support with the Synergy Pocket Micro-
ump (CircuLite, Inc., Saddle Brook, New Jersey) and have
aken an important step in that direction (1). The operation
ses a minimally invasive incision below the right clavicle
hat allows for pump outflow to the axillary artery (a
annulation technique that is becoming increasingly familiar
o cardiac surgeons as we deal with complex aortic pathol-
gy) and provides pump inflow through a more difficult
ccess approach, across the chest and through Waterston’s
roove into the left atrium. This seems to be a significant
mprovement compared with routine left ventricular assist
evice (LVAD) implants performed through a full sternot-
my, including a large pocket below the heart in the upper
bdomen for the pump itself. This new, small pump will sit
oughly where a right-side pacemaker would be placed.
atients chosen for this implant were generally not as sick as
ost patients undergoing LVAD implants. Fifteen of the
7 patients were INTERMACS (Interagency Registry for
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Bluhm Cardiovascular Institute, Division of Cardiothoracic Surgery ato
orthwestern University Feinberg School of Medicine and Northwestern Memorial
ospital, Chicago, Illinois.echanically Assisted Circulatory Support) class IV (recur-
ent hospital stays for heart failure). In contrast, INTER-
ACS class I or II (cardiogenic shock or progressive
ecline despite inotropes), as reported from the INTER-
ACS registry, account for 80% of recent LVAD implants
2). Partial support in this less-sick group of patients seems
o accomplish the hemodynamic effectiveness goals. There
as a significant improvement in cardiac index (2.0  0.4
/min/m2 increased to 2.8  0.6 l/min/m2, p  0.01) with
ignificant improvement in pulmonary artery diastolic pres-
ure and pulmonary capillary wedge pressure documented in
ater follow-up. Hemolysis was only detected in 1 patient.
linical outcomes were generally good, with 1 patient
equiring conversion to a different biventricular assist device
ystem, and 3 patient deaths. One death was due to sepsis
rom an unrecognized pre-existing renal abscess; 1 from
epsis of unknown origin; and 1 death occurred when a
atient discontinued his anticoagulation, developed pump
hrombosis, and subsequently had an embolization during
n explant of the device. The subset of patients who had
eak oxygen uptake measured showed a substantial im-
rovement (increasing by mean of 4.5  2.0 ml/kg/min),
hich would be clinically meaningful, and the B-type
atriuretic peptide dropped precipitously and was reduced
y 4,475  1,389 pg/ml.
However, partial support might have only been a partial
olution. The peak oxygen uptake, although significantly
igher, was still very low (14.1  1.6 ml/kg/min) and at a
evel where patients could still qualify as transplant candi-
ates. This might, however, reflect overall deconditioning
nd perhaps would improve with more time. Also, although
he B-type natriuretic peptide levels plummeted, they were
till extremely elevated with a value of 2,381  675 pg/ml.
istorically, there have been 3 major problems with chronic
echanical circulatory support: strokes or other embolic
vents, mechanical device failure, and infection (3). Al-
hough the authors report pocket hematomas, it does not
eem that infection around the device or drive line infection
as been a serious issue in this small, early experience. They
ad to increase the target international normalized ratio
evel because of pump thrombosis, which would lead to
otential embolic events.
Most concerning is that 8 of the first 12 patients required
ump exchange because of pump thrombosis. Fortunately, it
s a much simpler operation to replace this pump than
hanging many of the other LVADs. The authors describe
he procedure as lasting only 30 to 60 min. Also, fortu-
ately, they were able to identify design problems regarding
he wash-out channel within the pump rotor. The pump
as modified after stopping the clinical trial and performing
ench testing, and then they re-released a new pump with
nhanced washing within the rotor and a new target
nternational normalized ratio. With the new design and
nticoagulation strategy, they have not had further episodes
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Partial Mechanical Cardiac Support June 30, 2009:87–8upport of almost 4 months. However, it is a relatively short
uration of support, and their longest duration is only 7
onths in this article. One concern regarding partial sup-
ort has been that pumps might be more liable to develop
ump thrombosis at low flow. Unfortunately, this experi-
nce has not done anything to allay that concern.
In summary, we are embarking on a new phase of
echanical circulatory support when using small, less-
nvasive pumps for partial support in patients who are not
early as sick as those we have historically treated. There are
any encouraging signs in this experience such as the
mprovement in hemodynamic status, and this is the “proof
f concept” (1). There are some signs that this might be a
artial solution and that patients improved but, at least from
ome objective early measurements, were still far from
ormal. There is some concern that we might be creating a
roblem with pump thrombosis is becoming a more fre-
uent occurence than we see otherwise with pumps flowing
t 5 to 8 l/min. Despite these risks, the authors have
chieved good clinical outcomes similar to what we fre-
uently see with the bridge to transplantation (2). When
esigning a clinical trial for the Food and Drug Adminis-
ration, all of these considerations will be extremely impor-
K
dant. To justify use in earlier-stage heart failure patients, it
ill be very important to have a strong safety profile with
emodynamic improvement that translates into improved
linical condition. The authors should be congratulated on
his innovative work, and we eagerly anticipate more news.
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